| Status | In progress |
| Process | HST |
| ID number | 3764 |
Provisional Schedule
| Committee meeting: 1 | 06 October 2021 |
| Expected publication | 23 March 2022 |
Project Team
| Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email HST@nice.org.uk
| Evidence Review Group / Assessment Group | Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Consultees
| Companies sponsors | Rhythm Pharmaceuticals (setmelanotide) |
| Others | Department of Endocrinology, University Hospital Birmingham Foundation Trust |
| Department of Health and Social Care | |
| Great Ormond Street Hospital Metabolic Unit | |
| National Hospital for Neurology and Neurosurgery Charles Dent Metabolic Unit | |
| NHS England | |
| Salford Royal NHS Foundation Trust Mark Holland Metabolic Unit | |
| Willink Unit, Genetic Medicine, Central Manchester Foundation Trust | |
| Patient carer groups | BEAT |
| British Obesity Society | |
| British Obesity Surgery Patients Association | |
| Contact | |
| Findacure | |
| Genetic Alliance UK | |
| Healthier Weight Centres | |
| Muslim Council of Britain | |
| National Centre for Eating Disorders | |
| National Obesity Forum | |
| Obesity Health Alliance | |
| Obesity UK | |
| Overeaters Anonymous | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Weight Concern | |
| Professional groups | Association for the Study of Obesity |
| British Association of Endocrine and Thyroid Surgeons | |
| British Geriatrics Society | |
| British Nutrition Foundation | |
| British Obesity Surgery Society | |
| Nutrition Society | |
| Obesity Management Association | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Paediatrics & Child Health | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society for Endocrinology | |
| TREND UK | |
| UK Clinical Pharmacy Association | |
| UK Health Forum |
Commentators
| Associated public health groups | Faculty of Public Health Medicine |
| Public Health England | |
| Public Health Wales | |
| Comparator companies | Alissa Healthcare Research (orlistat) |
| Almus Pharmaceuticals (orlistat) | |
| Cheplapharm Arzneimittel (orlistat) | |
| Crescent Pharma (orlistat) | |
| GlaxoSmithKline Consumer Healthcare (orlistat) | |
| Teva UK (orlistat) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Inherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| National Services Division | |
| NHS Alliance | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane Metabolic & Endocrine Disorders Group |
| Cochrane Public Health Group | |
| Genomics England | |
| MRC Clinical Trials Unit, UCL | |
| National Institute for Health Research | |
| Wellcome-MRC Institute of Metabolic Science, Addenbrookes |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 May 2021 | Invitation to participate |
| 07 May 2021 | In progress. In progress |
| 31 July 2020 (14:00) | Scoping workshop (Manchester) |
| 08 June 2020 - 06 July 2020 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance